Bloomberg -- U.S. regulators approved Novartis AG’s Menveo meningococcal vaccine for use in children from 2 years of age, though they requested more information on use of the shot in infants.
Bloomberg -- U.S. regulators approved Novartis AG’s Menveo meningococcal vaccine for use in children from 2 years of age, though they requested more information on use of the shot in infants.